Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Three Months Ending March 31, 2021
March 26, 2021 at 08:05 pm IST
Share
Shanghai Haohai Biological Technology Co., Ltd. provided preliminary unaudited consolidated earnings guidance for the three months ending March 31, 2021, For the period, the group expects that the net profit will turn around as compared to the corresponding period in 2020. The group is expected to record an unaudited net profit attributable to shareholders of the listed company of approximately RMB 80,000,000 to RMB 100,000,000 (corresponding period in 2020: an unaudited net loss attributable to shareholders of the listed company of RMB 24,855,428.82). The unaudited net profit attributable to shareholders of the listed company after deducting the non-recurring profit or loss is expected to be approximately RMB 75,000,000 to RMB 95,000,000 (corresponding period in 2020: unaudited net loss attributable to shareholders of the listed company after deducting the non-recurring profit or loss of RMB 35,711,082.59).
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Earnings Guidance for the Three Months Ending March 31, 2021